Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Emergent BioSolutions stock | $49.85

Learn how to easily invest in Emergent BioSolutions stock.

Emergent BioSolutions Inc is a drug manufacturers-specialty & generic business based in the US. Emergent BioSolutions shares (EBS) are listed on the NYSE and all prices are listed in US Dollars. Emergent BioSolutions employs 2,200 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Emergent BioSolutions

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EBS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Emergent BioSolutions stock price (NYSE: EBS)

Use our graph to track the performance of EBS stocks over time.

Emergent BioSolutions shares at a glance

Information last updated 2021-10-24.
Latest market close$49.85
52-week range$49.35 - $127.20
50-day moving average $53.81
200-day moving average $60.80
Wall St. target price$85.71
PE ratio 9.0587
Dividend yield N/A (0%)
Earnings per share (TTM) $5.50

Buy Emergent BioSolutions shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Emergent BioSolutions stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Emergent BioSolutions price performance over time

Historical closes compared with the close of $49.85 from 2021-10-22

1 week (2021-10-15) N/A
1 month (2021-09-22) N/A
3 months (2021-07-26) -20.07%
6 months (2021-04-26) -22.10%
1 year (2020-10-26) -47.69%
2 years (2019-10-25) -9.38%
3 years (2018-10-26) 60.49
5 years (2016-10-26) 79.51%

Is Emergent BioSolutions under- or over-valued?

Valuing Emergent BioSolutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Emergent BioSolutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Emergent BioSolutions's P/E ratio

Emergent BioSolutions's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Emergent BioSolutions shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Emergent BioSolutions's PEG ratio

Emergent BioSolutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.55. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Emergent BioSolutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Emergent BioSolutions's EBITDA

Emergent BioSolutions's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $604.4 million.

The EBITDA is a measure of a Emergent BioSolutions's overall financial performance and is widely used to measure a its profitability.

Emergent BioSolutions financials

Revenue TTM $1.7 billion
Operating margin TTM 28.68%
Gross profit TTM $857.6 million
Return on assets TTM 11.38%
Return on equity TTM 21.82%
Profit margin 17.51%
Book value $28.75
Market capitalisation $2.7 billion

TTM: trailing 12 months

Shorting Emergent BioSolutions shares

There are currently 3.3 million Emergent BioSolutions shares held short by investors – that's known as Emergent BioSolutions's "short interest". This figure is 1.9% down from 3.3 million last month.

There are a few different ways that this level of interest in shorting Emergent BioSolutions shares can be evaluated.

Emergent BioSolutions's "short interest ratio" (SIR)

Emergent BioSolutions's "short interest ratio" (SIR) is the quantity of Emergent BioSolutions shares currently shorted divided by the average quantity of Emergent BioSolutions shares traded daily (recently around 416656.8877551). Emergent BioSolutions's SIR currently stands at 7.84. In other words for every 100,000 Emergent BioSolutions shares traded daily on the market, roughly 7840 shares are currently held short.

However Emergent BioSolutions's short interest can also be evaluated against the total number of Emergent BioSolutions shares, or, against the total number of tradable Emergent BioSolutions shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Emergent BioSolutions's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Emergent BioSolutions shares in existence, roughly 60 shares are currently held short) or 0.0754% of the tradable shares (for every 100,000 tradable Emergent BioSolutions shares, roughly 75 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Emergent BioSolutions.

Find out more about how you can short Emergent BioSolutions stock.

Emergent BioSolutions share dividends

We're not expecting Emergent BioSolutions to pay a dividend over the next 12 months.

Emergent BioSolutions share price volatility

Over the last 12 months, Emergent BioSolutions's shares have ranged in value from as little as $49.35 up to $127.2. A popular way to gauge a stock's volatility is its "beta".

EBS.US volatility(beta: 1.02)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Emergent BioSolutions's is 1.0249. This would suggest that Emergent BioSolutions's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Emergent BioSolutions overview

Emergent BioSolutions Inc. , a life sciences company, focuses on the provision of preparedness and response products and solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; and Trobigard, a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG for the treatment of SARS-CoV-2; FLU-IGIV for the treatment of seasonal influenza A virus; AV7909, an anthrax vaccine candidate; CHIKV VLP, a chikungunya virus VLP vaccine; ZIKV-IG, a zika therapeutic candidate; Shigella-ETEC, a shigella vaccine expressing ETEC antigens; EBS-LASV, a vector vaccine for Lassa fever; UNI-FLU, a universal influenza vaccine; rVSV-Marburg, a vector vaccine for treatment of Marburg virus disease; rVSV-Sudan, a vector vaccine for treatment of Sudan virus disease; DAT, a diphtheria antitoxin; Ricin-IG, a ricin antitoxin; and Pan-Ebola, a Ebola/Sudan monoclonal.

Frequently asked questions

What percentage of Emergent BioSolutions is owned by insiders or institutions?
Currently 9.446% of Emergent BioSolutions shares are held by insiders and 86.533% by institutions.
How many people work for Emergent BioSolutions?
Latest data suggests 2,200 work at Emergent BioSolutions.
When does the fiscal year end for Emergent BioSolutions?
Emergent BioSolutions's fiscal year ends in December.
Where is Emergent BioSolutions based?
Emergent BioSolutions's address is: 400 Professional Drive, Gaithersburg, MD, United States, 20879
What is Emergent BioSolutions's ISIN number?
Emergent BioSolutions's international securities identification number is: US29089Q1058
What is Emergent BioSolutions's CUSIP number?
Emergent BioSolutions's Committee on Uniform Securities Identification Procedures number is: 29089Q105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site